Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of RN6G in geographic atrophy secondary to age-related macular degeneration
2012-000823-42Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in age-related macular degeneration (AMD) and geographic atrophy (GA) comparing RN6G with Placebo (2 arms). Primary endpoint: Mean reduction in the rate of growth of geographic atrophy area. Started Aug 2012; status: terminated.
02
Drugs
RN6G
03
Conditions
age-related macular degeneration (AMD)geographic atrophy (GA)
Beyond the preview
Go deeper on 2012-000823-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000823-42.